wire - news in brief




Page not found (Error 404)





Category



Results 151 - 200 of 383.


Agronomy / Food Science - Event - 19.09.2019
Solutions for the future of nutritional research
Every day, we choose the food we eat and influence our health, whether consciously or not. This link between diet and health is a core concern of nutritional scientists, who met in Bern from 7 to 12 September 2019 for the 16th annual conference of the NuGO nutrigenomics association.

Materials Science - Event - 18.09.2019

Pharmacology - Health - 18.09.2019
FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis
There are currently no U.S. FDA-approved medicines for lupus nephritis The designation is based on the results of the phase II NOBILITY study that showed Gazyva, in combination with standard of care, helped more people achieve a complete renal response than standard of care alone Full results from the NOBILITY study will be presented at a medical meeting later this year Roche today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to Gazyva (obinutuzumab) for adults with lupus nephritis.

Health - Computer Science / Telecom - 17.09.2019
Prestigious grant to use Artificial Intelligence for improved glucose control
Prestigious grant to use Artificial Intelligence for improved glucose control
The ARTORG Center for Biomedical Engineering Research of the University of Bern is the recipient of a grant from JDRF, the leading global funder for type 1 diabetes research.

Pharmacology - Health - 17.09.2019
Novartis Cosentyx positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA).

Innovation - Business / Economics - 13.09.2019

Pharmacology - Health - 13.09.2019
Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis
Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS) ; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20 pos

Computer Science / Telecom - 13.09.2019

Pharmacology - Health - 13.09.2019
Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis
Post-hoc analysis from a Phase III open-label extension study showed a 42 percent reduction in the risk of PPMS patients needing a wheelchair after 6.5 years of OCREVUS treatment compared with patients who started OCREVUS after the double-blind period Interim analysis of Phase IIIb study shows 87 percent of patients with suboptimal response to previous treatment had no evidence of disease activity one year after switching to OCREVUS Separ

Pharmacology - Health - 13.09.2019
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer
New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment Data will be submitted to health authorities around the world, inc

Administration - Career - 13.09.2019
Gabriele Bavota earns an ERC Starting Grant to develop an artificial assistant for software developers
Gabriele Bavota, Assistant Professor at the USI Software Institute (SI), is among the recipients of the latest ERC Starting Grants, the research funds awarded by the European Research Council on a highly competitive basis to the most promising young researchers active in Europe.

Pharmacology - Health - 12.09.2019
Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum
Roche's satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum Pivotal phase III SAkuraStar study shows 55% reduction in the risk of rela

Pharmacology - Health - 12.09.2019
Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy
Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)Bullet Roche today announced positive data from the Phase

Earth Sciences - Computer Science / Telecom - 11.09.2019

Computer Science / Telecom - Microtechnics - 11.09.2019
A smart artificial hand for amputees merges user and robotic control
EPFL scientists have successfully tested new neuroprosthetic technology that combines robotic control with users' voluntary control, opening avenues in the new interdisciplinary field of shared control for neuroprosthetic technologies.  EPFL scientists are developing new approaches for improved control of robotic hands - in particular for amputees - that combines individual finger control and automation for improved grasping and manipulation.

Social Sciences - 11.09.2019
Growing Interest in Natural Sciences, Law and Economics
Growing Interest in Natural Sciences, Law and Economics
Next Monday, the Fall Semester begins for about 27,000 students at the University of Zurich. The number of Master's students in particular has increased.

Health - Life Sciences - 10.09.2019

Materials Science - 10.09.2019
EPFL's lightweight boat wins the 2019 HydroContest
EPFL's lightweight boat wins the 2019 HydroContest
This weekend in Yverdon, the HydroContest EPFL Team took first place in the nautical competition with its lightweight boat, second place in endurance, and third place in speed with its heavyweight boat.

Transport - Physics - 10.09.2019
Low-noise landing thanks to pilot assistance system
Low-noise landing thanks to pilot assistance system
Approach and landing are among the most complex phases of a flight.

Environment - Agronomy / Food Science - 10.09.2019
Climate protection thanks to agroforestry
Zurich-Reckenholz, 10.09.2019 - Producing food and feed while protecting the climate - is that possible? Yes, and agroforestry is one option, combining agriculture and wood production on the same land.

Life Sciences - Health - 10.09.2019
Wyss Center and Osypka announce collaboration
Wyss Center and Osypka announce collaboration
Today the Wyss Center for Bio and Neuroengineering, Geneva, Switzerland and OSYPKA AG/OSYPKA Medtec, Rheinfelden, Germany and Longmont, Colorado, USA, announced a collaboration to develop and integrate innovative technologies into implantable neuro-devices.

Life Sciences - Health - 10.09.2019

Pharmacology - Health - 10.09.2019
Roche presents new OCREVUS (ocrelizumab) biomarker data that increase understanding of disease progression in multiple sclerosis at ECTRIMS
Blood neurofilament light chain (NfL) levels were significantly lowered following OCREVUS treatment in analyses of Phase III studies in RMS and PPMS New data show NfL may be a biomarker for predicting future disability outcomes Separate analyses presented from one of the first studies to demonstrate NfL levels are correlated with active MRI lesions in PPMS Roche today announced new data from OCREVUS (ocrelizumab) trials in relapsing and primary progressive multiple sclerosis (MS).

Computer Science / Telecom - Social Sciences - 10.09.2019
Three Ways to Cultivate Talents like David Yenicelik
Three Ways to Cultivate Talents like David Yenicelik
Universities play an increasingly important role in society creating an environment where talents, like graduate student David Yenicelik, thrive.

Pharmacology - Health - 09.09.2019
Novartis data confirm long-term efficacy and safety of Aimovig for majority of patients with episodic migraine
The 5-year open-label treatment period (OLTP) examines sustained efficacy and long-term safety of Aimovig (erenumab) in patients with episodic migraine, starting on 70mg and switched after two years

Academic Rankings - 09.09.2019

Pharmacology - Health - 06.09.2019
European Commission approves Roche’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
Tecentriq in combination with chemotherapy (carboplatin and etoposide) is the first and only cancer immunotherapy approved by the European Medicines Agency for the initial treatment of extensive-stag

Health - 05.09.2019
Vontobel Award: Systematic Remembering and Similar Surgical Consequences
This year's Vontobel Award for Research on Age(ing) goes to Burcu Demiray Batur from the University of Zurich, Jonathan Rychen from the University Hospital of Basel and Sarah Stricker from the Hôpital Necker in Paris.

Innovation - Business / Economics - 05.09.2019

Event - Microtechnics - 05.09.2019
EPFL marks its 50th anniversary with a two-day open house
EPFL marks its 50th anniversary with a two-day open house
EPFL will open its doors to the public on 14-15 September as it celebrates its 50th year as a federal institute of technology.

Administration - Career - 04.09.2019

Environment - Business / Economics - 04.09.2019
Turning companies into allies
Turning companies into allies
She was involved in developing the world's most accurate clock, and now she helps companies adopt more sustainable business practices: Petrissa Eckle, Executive Director of the Sustainability in Business Lab at ETH Zurich.

Pharmacology - Health - 04.09.2019
Roche to present pivotal data for satralizumab in neuromyelitis optica spectrum disorder and six-year OCREVUS data in multiple sclerosis at ECTRIMS
Investigational medicine satralizumab significantly reduces the risk of relapse in pivotal SAkuraStar monotherapy study for neuromyelitis optica spectrum disorder New data provide insights into neurofilament light chain levels as a potential biomarker for predicting MS disability progression; new longer-term OCREVUS (ocrelizumab) data of more than six years show reduction of disability progression in relapsing and primary progressive MS Breadth

Career - Administration - 03.09.2019